Sign in Subscribe
Vaccines

COVID-19 Vaccines Show Excellent Safety and Efficacy in Radiation-Oncology Patients

Strategic Insights

— 1 min read

A recent study has found that COVID-19 vaccines demonstrate excellent safety, immunogenicity, and efficacy in patients receiving radiation oncology treatment. The systematic review and meta-analysis of 22 studies conducted between 2021 and 2024 found that patients undergoing radiation therapy exhibited a high willingness to receive vaccination, and the vaccines were overall well-tolerated and safe. The primary meta-analysis showed a seroconversion proportion of 91% overall, with a higher proportion in patients receiving radiation therapy alone compared to those receiving radiation therapy combined with chemotherapy.

Key Takeaways:

  • COVID-19 vaccines demonstrate excellent safety, immunogenicity, and efficacy in patients receiving radiation oncology treatment, with a high willingness to be vaccinated.
  • The vaccines were overall well-tolerated and safe, with a low incidence of side effects, which were primarily mild.
  • The primary meta-analysis showed a seroconversion proportion of 91% overall, with a higher proportion in patients receiving radiation therapy alone compared to those receiving radiation therapy combined with chemotherapy.
  • Patients receiving radiation therapy exhibited a sustained increase in antibody titers, with a notable long-term persistence of IgG.
  • The outcomes observed are comparable to those in healthy controls and superior to those seen in patients receiving other cancer treatments, such as chemotherapy.
  • The vaccination of radiation oncology patients in future pandemics or epidemics is strongly advocated, even during active treatment.

Statistics:

  • Seroconversion proportion: 91% (95% CI: 84-96%) overall
  • Seroconversion proportion in patients receiving radiation therapy alone: 93% (95% CI: 86-96%)
  • Seroconversion proportion in patients receiving radiation therapy combined with chemotherapy: 90% (95% CI: 83-94%)
  • Incidence of side effects: low
  • Keywords: COVID-19, Radiation-Oncology Patients, Vaccines, Immunization, Public Health, Biological Products, Drugs and Therapies

Sources:

  • "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Radiation-Oncology Patients: A Systematic Review and Meta-Analysis." Vaccines, 2025, 13(7):715. (Vaccines - http://www.mdpi.com/journal/vaccines). The publisher for Vaccines is MDPI AG.
  • NewsRx LLC. Findings from Linz in COVID-19 Reported (Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Radiation-Oncology Patients: A Systematic Review and Meta-Analysis). Cancer Weekly. August 12, 2025; p 200.

Read more